Krystal Biotech, Inc. — Director's Dealing 2020

May 19, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2020-05-15

Reporting Person: Krishnan Krish S (Director, President and CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-15	Common Stock	S	3842	$57.4282	Disposed	1932620	Direct
2020-05-15	Common Stock	S	12445	$58.0854	Disposed	1920175	Direct
2020-05-15	Common Stock	S	10552	$59.029	Disposed	1909623	Direct
2020-05-18	Common Stock	S	2900	$55.985	Disposed	1906723	Direct
2020-05-18	Common Stock	S	6784	$56.838	Disposed	1899939	Direct
2020-05-18	Common Stock	S	5371	$57.6302	Disposed	1894568	Direct
2020-05-18	Common Stock	S	1805	$59.113	Disposed	1892763	Direct
2020-05-18	Common Stock	S	6301	$59.7278	Disposed	1886462	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	112162	Indirect
Common Stock	1936064	Indirect

Footnotes

F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors.

F2: This transaction was executed in multiple trades ranging from $56.65 to $57.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F3: This transaction was executed in multiple trades ranging from $57.65 to $58.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F4: This transaction was executed in multiple trades ranging from $58.69 to $59.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F5: This transaction was executed in multiple trades ranging from $55.36 to $56.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F6: This transaction was executed in multiple trades ranging from $56.37 to $57.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F7: This transaction was executed in multiple trades ranging from $57.37 to $58.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F8: This transaction was executed in multiple trades ranging from $58.40 to $59.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F9: This transaction was executed in multiple trades ranging from $59.42 to $60.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

F10: Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.

F11: Directly beneficially owned by Suma S. Krishnan, the spouse of the reporting person.